Evidence map›Paper›PMID 40078291›Full record

ArticleFrontiers in pharmacology2025

A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy.

Shizhu Zhang, Nan Wu, Yifei Geng, Lixia Guan, Miao-Miao Niu, Jindong Li, Lusha Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shizhu Zhang *Department of Nephrology, Huai'an Cancer Hospital, Huai'an, China.
Nan Wu *Department of Nephrology, Huai'an Cancer Hospital, Huai'an, China.
Yifei GengDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Lixia GuanDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Miao-Miao NiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Jindong LiDepartment of Pharmacy, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Lusha ZhuDepartment of Pharmacy, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concurrent inhibition of bromodomain-containing protein 4 (

Indexed as

bromodomain-containing protein 4 (BRD4)dual-targeted inhibitorsrenal cell carcinomasignal transductor and activator of transcription 3 (STAT3)virtual screening

Identifiers

PMID40078291
PMCPMC11897524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.